Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2006 1
2007 3
2008 1
2009 5
2010 1
2011 2
2012 1
2013 3
2014 4
2015 4
2016 7
2017 10
2018 11
2019 7
2020 13
2021 12
2022 5
2023 1
2024 3
2025 1
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment.
Yamamichi G, Kato T, Arakawa N, Ino Y, Ujike T, Nakano K, Koh Y, Motoyama Y, Outani H, Myoba S, Ishizuya Y, Yamamoto Y, Hatano K, Kawashima A, Fukuhara S, Uemura H, Okada S, Morii E, Nonomura N, Uemura M. Yamamichi G, et al. Among authors: ujike t. Biomark Res. 2024 Nov 25;12(1):147. doi: 10.1186/s40364-024-00695-6. Biomark Res. 2024. PMID: 39587633 Free PMC article.
Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility.
Hayashi T, Kawashima A, Yamamoto Y, Ishizuya Y, Horitani H, Inoguchi S, Horibe Y, Sassi N, Hayashi Y, Ujike T, Nakano K, Miyake O, Takayama H, Yazawa K, Tsutsui K, Kurahashi Y, Nakata W, Asakura T, Murakawa T, Okada K, Nakayama M, Kato T, Hatano K, Nonomura N. Hayashi T, et al. Among authors: ujike t. Jpn J Clin Oncol. 2026 Jul 20:hyag117. doi: 10.1093/jjco/hyag117. Online ahead of print. Jpn J Clin Oncol. 2026. PMID: 42476103 Free article.
Clinical implications of serum GDF15 propeptide as a biomarker for bone metastasis across common solid tumors: a real-world multi-institutional study.
Yamamichi G, Kato T, Matsukawa A, Masunaga N, Hirata H, Okuno J, Kawamura N, Kunimasa K, Seto I, Kin T, Masuhiro K, Sato S, Myoba S, Ikeda S, Ujike T, Ishizuya Y, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Miyagi Y, Uemura M, Nishino K, Nakayama T, Nakayama M, Takeda Y, Shimazu K, Nonomura N. Yamamichi G, et al. Among authors: ujike t. Biomark Res. 2026 Aug 12;14(1):88. doi: 10.1186/s40364-026-00982-4. Biomark Res. 2026. PMID: 42587303 Free PMC article.
[PROGNOSTIC FACTORS FOR METASTATIC UROTHELIAL CARCINOMA IN THE IMMUNOTHERAPY ERA].
Tsujimoto Y, Nakamura M, Kurahashi Y, Mori S, Mizuno R, Okada K, Nakata W, Ujike T, Nin M, Tsujihata M. Tsujimoto Y, et al. Among authors: ujike t. Nihon Hinyokika Gakkai Zasshi. 2024;115(4):156-162. doi: 10.5980/jpnjurol.115.156. Nihon Hinyokika Gakkai Zasshi. 2024. PMID: 41110968 Free article. Japanese.
Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinoma.
Hayashi Y, Kawashima A, Yamamoto Y, Hayashi T, Ishizuya Y, Horitani H, Inoguchi S, Horibe Y, Sassi N, Ujike T, Takao T, Umeda S, Takayama H, Yazawa K, Tsutsui K, Yamazaki H, Inoue H, Asakura T, Kobayashi M, Okada K, Nakayama M, Kato T, Hatano K, Nonomura N. Hayashi Y, et al. Among authors: ujike t. Cancer Treat Res Commun. 2026;48:101255. doi: 10.1016/j.ctarc.2026.101255. Epub 2026 May 22. Cancer Treat Res Commun. 2026. PMID: 42214276 Free article.
Gut Microbiota-Derived Short-Chain Fatty Acids Promote Prostate Cancer Growth via IGF1 Signaling.
Matsushita M, Fujita K, Hayashi T, Kayama H, Motooka D, Hase H, Jingushi K, Yamamichi G, Yumiba S, Tomiyama E, Koh Y, Hayashi Y, Nakano K, Wang C, Ishizuya Y, Kato T, Hatano K, Kawashima A, Ujike T, Uemura M, Imamura R, Rodriguez Pena MDC, Gordetsky JB, Netto GJ, Tsujikawa K, Nakamura S, Takeda K, Nonomura N. Matsushita M, et al. Among authors: ujike t. Cancer Res. 2021 Aug 1;81(15):4014-4026. doi: 10.1158/0008-5472.CAN-20-4090. Epub 2021 May 26. Cancer Res. 2021. PMID: 34039634
High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling.
Hayashi T, Fujita K, Nojima S, Hayashi Y, Nakano K, Ishizuya Y, Wang C, Yamamoto Y, Kinouchi T, Matsuzaki K, Jingushi K, Kato T, Kawashima A, Nagahara A, Ujike T, Uemura M, Pena MDCR, Gordetsky JB, Morii E, Tsujikawa K, Netto GJ, Nonomura N. Hayashi T, et al. Among authors: ujike t. Clin Cancer Res. 2018 Sep 1;24(17):4309-4318. doi: 10.1158/1078-0432.CCR-18-0106. Epub 2018 May 18. Clin Cancer Res. 2018. PMID: 29776955
Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma.
Kawashima A, Kanazawa T, Kidani Y, Yoshida T, Hirata M, Nishida K, Nojima S, Yamamoto Y, Kato T, Hatano K, Ujike T, Nagahara A, Fujita K, Morimoto-Okazawa A, Iwahori K, Uemura M, Imamura R, Ohkura N, Morii E, Sakaguchi S, Wada H, Nonomura N. Kawashima A, et al. Among authors: ujike t. Sci Rep. 2020 Apr 10;10(1):6220. doi: 10.1038/s41598-020-63060-1. Sci Rep. 2020. PMID: 32277125 Free PMC article.
Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma.
Koh Y, Nakano K, Katayama K, Yamamichi G, Yumiba S, Tomiyama E, Matsushita M, Hayashi Y, Yamamoto Y, Kato T, Hatano K, Kawashima A, Ujike T, Imamura R, Yamaguchi R, Imoto S, Shiotsu Y, Nonomura N, Uemura M. Koh Y, et al. Among authors: ujike t. Int J Urol. 2022 May;29(5):462-469. doi: 10.1111/iju.14816. Epub 2022 Feb 19. Int J Urol. 2022. PMID: 35184335 Free PMC article.
93 results